Impact of hematologic toxicities during concurrent chemoradiation for cervical cancer
Feiya Shi, Alison K. Yoder, Claire Mach, Shraddha Dalwadi, Matthew L Anderson, Tracilyn R Hall, Michelle S Ludwig
Obstet Gynecol Sci. 2022;65(2):176-187.   Published online 2022 Feb 22     DOI:
Citations to this article as recorded by Crossref logo
Clinical outcome after high dose rate intracavitary brachytherapy with traditional point ‘A’ dose prescription in locally advanced carcinoma of uterine cervix: dosimetric analysis from the perspective of computed tomography imaging-based 3-dimensional tre
Suman Dhabal, Abhishek Basu, Saikat Sau, Sourav Sau, Pradip Kumar Maiti, Abhay Chakravarty
Obstetrics & Gynecology Science.2024; 67(1): 67.     CrossRef
Radiation-induced lymphopenia and the survival of women with cervical cancer: a meta-analysis
Hongming Cao, Haiyan Yan, Shoumin Bai, Baihui Gu
Journal of Obstetrics and Gynaecology.2023;[Epub]     CrossRef
Pretreatment total lymphocyte count as a prognostic factor of survival in patients with recurrent cervical cancer after definitive radiation-based therapy: a retrospective study
Ekasak Thiangphak, Kittinun Leetanaporn, Rakchai Buhachat
Obstetrics & Gynecology Science.2023; 66(5): 407.     CrossRef
Development of a nomogram for predicting grade 2 or higher acute hematologic toxicity of cervical cancer after the pelvic bone marrow sparing radiotherapy
Xiangdi Meng, Nan Wang, Meng Yu, Dechen Kong, Zhengtao Zhang, Xiaolong Chang, Yinghua Guo, Yang Li
Frontiers in Public Health.2022;[Epub]     CrossRef